Efficacy of Baricitinib Compared to Conventional Therapy for Alopecia Areata

The study compares the efficacy of Baricitinib, a JAK inhibitor, to conventional corticosteroid treatments for Alopecia Areata (AA), an autoimmune condition causing patchy hair loss. Baricitinib, approved by the FDA in 2022, targets the JAK enzymes involved in the inflammation of hair follicles, potentially offering a more effective treatment option. The research involved screening 19 manuscripts and found that while Baricitinib is effective, it may cause adverse reactions in patients with specific health histories. The study emphasizes the importance of evaluating individual patient history to ensure safety and efficacy when prescribing Baricitinib.